Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
2007 1
2008 1
2009 1
2015 1
2020 1
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Tawbi HA, et al. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. N Engl J Med. 2022. PMID: 34986285 Free PMC article. Clinical Trial.
Role of Annexin A1 Secreted by Neutrophils in Melanoma Metastasis.
Sandri S, Hebeda CB, Broering MF, de Paula Silva M, Moredo LF, de Barros E Silva MJ, Sapata Molina A, Lopes Pinto CA, Duprat Neto JP, Reutelingsperger CP, Gil CD, Farsky SHP. Sandri S, et al. Among authors: de barros e silva mj. Cells. 2023 Jan 27;12(3):425. doi: 10.3390/cells12030425. Cells. 2023. PMID: 36766767 Free PMC article.
Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors.
de Britto Evangelista GF, Figueiredo AB, de Barros E Silva MJ, Gollob KJ. de Britto Evangelista GF, et al. Among authors: de barros e silva mj. Immunother Adv. 2022 Apr 8;2(1):ltac008. doi: 10.1093/immadv/ltac008. eCollection 2022. Immunother Adv. 2022. PMID: 35919497 Free PMC article. Review.
Tuberculosis in a patient on temozolomide: a case report.
de Paiva TF Jr, de Barros e Silva MJ, Rinck JA Jr, Fanelli MF, Gimenes DL. de Paiva TF Jr, et al. Among authors: de barros e silva mj. J Neurooncol. 2009 Mar;92(1):33-5. doi: 10.1007/s11060-008-9724-0. Epub 2008 Nov 1. J Neurooncol. 2009. PMID: 18974931
Health resource utilisation by patients with neuroendocrine tumours with or without carcinoid heart disease: a multinational study.
Tanaka H, Uema D, Rego JFM, Weschenfelder RF, D'Agustini N, Filho DRR, O'Connor JM, Luca R, Nuñez JER, de Barros E Silva MJ, Riechelmann RP. Tanaka H, et al. Among authors: de barros e silva mj. Ecancermedicalscience. 2020 Nov 13;14:1141. doi: 10.3332/ecancer.2020.1141. eCollection 2020. Ecancermedicalscience. 2020. PMID: 33343700 Free PMC article.
Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC, Karen de Sá V, Sternberg C, Olivieri ER, Werneck da Cunha I, Fabro AT, Carraro DM, de Barros e Silva MJ, Pimenta Inada HK, de Mello ES, Soares FA, Takagaki T, Ferreira CG, Capelozzi VL. de Melo AC, et al. Among authors: de barros e silva mj. Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1. Oncology. 2015. PMID: 25833149
11 results